CTI BioPharma Corp. (NASDAQ:CTIC) shares, rose in value on Friday, May 26, with the unchanged stock price to the previous day’s close as strong demand from buyers drove the stock to $9.02.
Actively observing the price movement in the recent trading, the stock is buoying the session at $9.02, falling within a range of $9.01 and $9.03. The value of beta (5-year monthly) is 0.87. Referring to stock’s 52-week performance, its high was $9.05, and the low was $4.01. On the whole, CTIC has fluctuated by 88.31% over the past month.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
With the market capitalization of CTI BioPharma Corp. currently standing at about $1.19 billion, investors are eagerly awaiting this quarter’s results, scheduled for Aug 07, 2023 – Aug 11, 2023. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.08, which is expected to increase to -$0.02 for fiscal year -$0.27 and then to about $0.31 by fiscal year 2024. Data indicates that the EPS growth is expected to be 66.70% in 2024, while the next year’s EPS growth is forecast to be 214.80%.
Analysts have estimated the company’s revenue for the quarter at $28.33 million, with a low estimate of $25.83 million and a high estimate of $30.7 million. According to the average forecast, sales growth in current quarter could jump up 129.80%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2024, the company’s y-o-y revenues would reach $123.32 million, representing an increase of 128.60% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were 1 upward and no downward review(s) in last seven days. We see that CTIC’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 50% Buy.
9 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 6 analyst(s), 3 recommend it as a Buy and 0 called the CTIC stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Overweight.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of CTIC currently trading nearly 22.92% and 60.21% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 85.69, while the 7-day volatility ratio is showing 0.41% which for the 30-day chart, stands at 2.10%. Furthermore, CTI BioPharma Corp. (CTIC)’s beta value is 0.75, and its average true range (ATR) is 0.24. The company’s stock has been forecasted to trade at an average price of $10.30 over the course of the next 52 weeks, with a low of $9.00 and a high of $15.00. Based on these price targets, the low is 0.22% off current price, whereas the price has to move -66.3% to reach the yearly target high. Additionally, analysts’ median price of $9.10 is likely to be welcomed by investors because it represents a decrease of -0.89% from the current levels.
A comparison of CTI BioPharma Corp. (CTIC) with its peers suggests the former has fared considerably weaker in the market. CTIC showed an intraday change of 0.00% in today’s session so far, and over the past year, it grew by 69.55%%. In comparison, Eli Lilly and Company (LLY) has moved lower at -0.23% today and is up 38.87% over the past 12 months. On the other hand, the price of Madrigal Pharmaceuticals Inc. (MDGL) has fallen -0.20% today. The stock, however, is off 324.92% from where it was a year ago. Additionally, there is a loss of -0.43% for Bristol-Myers Squibb Company (BMY) in recent trading while the stock has seen an overall depriciation of -16.77%% over the past year. Other than that, the overall performance of the S&P 500 during the today’s session so far shows that it gained 1.04%. Meanwhile, the Dow Jones Industrial Improved by 0.94%.
Data on historical trading for CTI BioPharma Corp. (NASDAQ:CTIC) indicates that the trading volumes over the past 10 days have averaged 6.61 million and over the past 3 months, they’ve averaged 5.88 million. According to company’s latest data on outstanding shares, there are 131.57 million shares outstanding.
Nearly 5.50% of CTI BioPharma Corp.’s shares belong to company insiders and institutional investors own 79.30% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 8.08 million shares as on May 14, 2023, resulting in a short ratio of 0.78. According to the data, the short interest in CTI BioPharma Corp. (CTIC) stood at 6.13% of shares outstanding as of May 14, 2023; the number of short shares registered in Apr 13, 2023 reached 16.05 million. The stock has risen by 50.08% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CTIC stock heading into the next quarter.